Episodes
S4, E3: Inside Opus Genetics’ Pivot – Skepticism, Proxy Fights and a Comeback, with CEO George Magrath
In this episode, Surani speaks with George Magrath, CEO of Opus Genetics, about the realities of leading a public biotech company through a major strategic pivot and intense market scrutiny. Opus Gene...
S4, E2: From Medicine to IPOs - Dr Sheila Gujrathi on Raising Biotech Against the Odds
In this episode, we focus on the personal journey of Sheila Gujrathi, a physician turned biotech builder whose career spans medicine, big pharma, rapid IPOs, and billion dollar exits. We explore what ...
S4, E1: From the Archive - Revisiting eGenesis and Xenotransplantation with Pig Organs, Two Years On
In this early-January episode, we slow things down, and reflect... Today’s episode is a replay from the Raising Biotech archive — a conversation originally recorded in November 2023 with eGenesis, a c...
S3, E6: Veradermics puts hair loss back on the investor agenda with $150 million Series C - with CEO Dr Reid Waldman and InThought's Julie Hoggatt
In this episode, we dive into one of the most universal aesthetic concerns on the planet: pattern hair loss. Despite affecting more than 80 million people in the US and over a billion globally, innova...
S3, E5: Special Analysis: What's going on with European Biotech? - Reporting from BioEurope in Vienna
In this special on-the-ground episode of Raising Biotech, Surani takes you inside BIO-Europe 2025 in Vienna — the dealmaking, the caffeine, and the cautious optimism shaping Europe’s biotech landscape...
S3, E4: ReproNovo’s strategic trash-to-treasure bet on fertility and reproductive health - with CEO Jean Marie Duval
In this episode, we dive into ReproNovo’s “trash to treasure” biotech story. Founded in Switzerland in 2021, the company is reimagining reproductive medicine, one of the most underserved areas in biot...
S3, E3: AltruBio’s Cinderella story from bankruptcy talks to a $225M Series B to tackle autoimmune diseases - with CEO Dr Judy Chou
In this episode, we look at AltruBio’s Cinderella story. While the company officially launched in 2020, its roots go back more than 20 years with a rich immunology pipeline stuck in “academic-style ex...
S3, E2: The Biotech Bromance: Serial CEO and Investor’s 20‑Year Journey of Building Biotechs with Steve Butts, Arrivo Bio and Dave Adair, Solas BioVentures
This episode of Raising Biotech takes a different turn — not just the story of a biotech, but of a partnership. Steve Butts, CEO of Arrivo BioVentures, and Dr. Dave Adair, Co‑Founder and Managing Part...
S3, E1: How Xaira Therapeutics went from incubation to a billion dollar launch - with Vik Bajaj, CEO Foresite Labs
In this episode, we go inside the creation of Xaira Therapeutics — the biotech startup that raised over a billion dollars at launch without a product or clinical data. Speaking with Vik Bajaj, CEO and...